Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- SANN.SW
- Price
- 13.16
- Stock movement up
- +0.72 (5.79%)
- Company name
- Santhera Pharmaceuticals Holding AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 176.15M
- Ent value
- 291.08M
- Price/Sales
- 2.51
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.41%
- 1 year return (CAGR)
- -6.00%
- 3 year return (CAGR)
- 143.81%
- 5 year return (CAGR)
- 36.37%
- 10 year return (CAGR)
- -15.98%
Last updated: 2026-02-13
DIVIDENDS
SANN.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.51 |
| Price to Book | - |
| EV to Sales | 4.15 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 13.39M |
| EPS (TTM) | -6.92 |
| FCF per share (TTM) | -4.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 70.19M |
| Gross profit (TTM) | 19.24M |
| Operating income (TTM) | -77.64M |
| Net income (TTM) | -88.44M |
| EPS (TTM) | -6.92 |
| EPS (1y forward) | -0.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 27.41% |
| Operating margin (TTM) | -110.62% |
| Profit margin (TTM) | -126.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 18.40M |
| Net receivables | 11.20M |
| Total current assets | 58.80M |
| Goodwill | 0.00 |
| Intangible assets | 66.44M |
| Property, plant and equipment | 0.00 |
| Total assets | 130.77M |
| Accounts payable | 24.44M |
| Short/Current long term debt | 76.30M |
| Total current liabilities | 57.78M |
| Total liabilities | 133.33M |
| Shareholder's equity | -2.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -63.77M |
| Capital expenditures (TTM) | 187.00K |
| Free cash flow (TTM) | -56.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -67.63% |
| Return on Invested Capital | -197.48% |
| Cash Return on Invested Capital | -125.66% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.50 |
| Daily high | 13.16 |
| Daily low | 12.50 |
| Daily Volume | 123K |
| All-time high | 134.40 |
| 1y analyst estimate | 30.00 |
| Beta | -0.74 |
| EPS (TTM) | -6.92 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 27 Apr 2026 |
Downside potential
Loading...
Downside potential data
| SANN.SW | S&P500 | |
| Current price drop from All-time high | -90.21% | -0.89% |
| Highest price drop | -99.63% | -56.47% |
| Date of highest drop | 2 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -76.42% | -10.86% |
| Avg time to new high | 597 days | 12 days |
| Max time to new high | 2598 days | 1805 days |
COMPANY DETAILS
Marketcap
176.15M
Marketcap category
Small-cap
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Employees
78
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the rel...
February 13, 2026
Pratteln, Switzerland, February 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced the appointment of Stifel Nicolaus Europe Limited (“Stifel”) as corporate finance advisor with a focus o...
February 10, 2026
Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissme...
January 15, 2026
Under the agreement, Santhera will receive an initial payment of $40m from Nxera.
January 9, 2026
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, ...
January 8, 2026
Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support t...
November 5, 2025
Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen...
November 4, 2025
Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, fo...
October 9, 2025
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Prat...
October 3, 2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced...
September 25, 2025
Next page